Cyclophosphamide is an anti-cancer drug that acts upon the immune system, dampening its response. It’s used in chemotherapy for breast cancer, lymphoma and other cancers, and also used to treat autoimmune diseases such as lupus, rheumatoid arthritis and multiple sclerosis. Now, trials are being held to determine whether the drug can benefit ME/CFS patients as well.
A phase two trial of cyclophosphamide is currently being carried out by Norwegian researchers, headed by Dr Øystein Fluge and Professor Olav Mella. You may recognise the names from the very promising rituximab studies that they have been involved with. In fact, this new study is focussed on patients whom either relapsed after treatment with rituximab, or didn’t respond to it at all.